Lupin looking at acquisitions in US
The company is looking at inorganic growth options in order to bolster its overseas presence.
New Delhi, October 29, 2014: With a view to increase its overseas presence, the Indian drug major Lupin is looking at acquisitions in the US, mainly in the inhalers and injectables segment. The company continues to evaluate opportunities and the acquisitions in the US with a view to create a strong speciality business and bolstering its existing brand business and acquiring technological capabilities.
Being the world’s largest drug market, the company is aiming for a growth rate of 25 per cent in the US market. Lupin is currently the fifth largest and the fastest growing top five generic players in the US for the third year now.
As of June 30, 2014, the company's cumulative abbreviated new drug application (ANDA) filing with the US Food and Drug Administration (USFDA) stood at 200 with the company having received 103 approvals.